NAT2 genotyping: Equilibrium between accuracy and feasibility in routine analyses

Journal of Applied Research

Volumn 3, Issue 2, 2003, Pages 118-123

  Agúndez, José A G ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Metabolism; Pharmacogenomics; Polymorphism

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENE; GENE FREQUENCY; HUMAN; NAT2 GENE; PHARMACOGENOMICS; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; XENOBIOTIC METABOLISM;

EID: 0141792604     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Clark DWJ: Genetically determined variability in acetylation and oxidation. Drugs 38:2798-2802, 1985.
2. Evans DAP: Genetic factors in drug therapy. Clinical and Molecular Pharmacogenetics. Cambridge: Cambridge University Press; 1993.
3. Crook JE, Woosley RL, Leftwich RB, Natelson EA: Agranulocytosis during combined procainamide and phenytoin therapy. South Med J 72:1599-1601, 1979.
4. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296, 1997.
5. Vatsis KP, Weber WW, Bell DA, et al: Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17, 1995.
6. Agúndez JA, Olivera M, Martinez C, Ladero JM, Benitez J: Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 6:423-428, 1996.
7. Martinez C, Agúndez JA, Olivera M, Martin R, Ladero JM, Benitez J: Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5:207-214, 1995.
8. Agúndez JA, Menaya JG, Tejeda R, Lago F, Chaves M, Benitez J: Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics 6:465-472, 1996.
9. Agúndez JA, Olivera M, Ladero JM, et al: Increased risk of hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 6:501-512, 1996.
10. Agúndez JA, Martinez C, Olivera M, et al: Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Brit J Cancer 78:1361-1367, 1998.
11. Agúndez JA, Jimenez.Jimenez FJ, Luengo A, et al: Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 51:1587-1592, 1998.
12. Lin HJ, Han C-Y, Lin BK, Hardy S: Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134, 1994.
13. Bell DA, Taylor JA, Butler MA, et al: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692, 1993.
14. Martinez C, Agúndez JA, Olivera M, et al: Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 63:623-628, 1998.